WO2004011464A3 - Nouvelles pyrazolo[1,5-a]-1,3,5-triazines substituees et leurs analogiques, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation - Google Patents

Nouvelles pyrazolo[1,5-a]-1,3,5-triazines substituees et leurs analogiques, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation Download PDF

Info

Publication number
WO2004011464A3
WO2004011464A3 PCT/FR2003/002354 FR0302354W WO2004011464A3 WO 2004011464 A3 WO2004011464 A3 WO 2004011464A3 FR 0302354 W FR0302354 W FR 0302354W WO 2004011464 A3 WO2004011464 A3 WO 2004011464A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
analogues
triazine derivatives
same
medicine
Prior art date
Application number
PCT/FR2003/002354
Other languages
English (en)
Other versions
WO2004011464A2 (fr
Inventor
Philippe Bernard
Pierre Raboisson
Benoit Joseph
Original Assignee
Greenpharma Sas
Philippe Bernard
Pierre Raboisson
Benoit Joseph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenpharma Sas, Philippe Bernard, Pierre Raboisson, Benoit Joseph filed Critical Greenpharma Sas
Priority to US10/522,497 priority Critical patent/US20060106019A1/en
Priority to EP03755633A priority patent/EP1525205A2/fr
Priority to JP2004523885A priority patent/JP4794856B2/ja
Priority to AU2003273473A priority patent/AU2003273473A1/en
Priority to CA2493402A priority patent/CA2493402C/fr
Publication of WO2004011464A2 publication Critical patent/WO2004011464A2/fr
Publication of WO2004011464A3 publication Critical patent/WO2004011464A3/fr
Priority to US12/315,201 priority patent/US20090105261A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)

Abstract

L'invention concerne notamment de nouveaux dérivés de pyrazolo[1,5-a]-1,3,5-triazines ainsi que certains de leurs analogues structuraux et leurs applications dans le domaine thérapeutique tout particulièrement pour la prévention et le traitement de pathologies impliquant une dégénérescence des neurones centraux et/ou périphériques. Elle concerne également des procédés pour leur préparation et de nouveaux intermédiaires de synthèse. Les composés de l'invention répondent plus particulièrement aux formules générales (Ia) et (Ib).
PCT/FR2003/002354 2002-07-26 2003-07-25 Nouvelles pyrazolo[1,5-a]-1,3,5-triazines substituees et leurs analogiques, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation WO2004011464A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/522,497 US20060106019A1 (en) 2002-07-26 2003-07-25 Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same
EP03755633A EP1525205A2 (fr) 2002-07-26 2003-07-25 Nouvelles pyrazolo(1,5-a)-1,3,5-triazines substituees et leurs analogiques, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation
JP2004523885A JP4794856B2 (ja) 2002-07-26 2003-07-25 新規置換ピラゾロ〔１，５‐ａ〕‐１，３，５‐トリアジン誘導体およびそれらの類似体、それを含有した医薬組成物、医薬品としてのその使用、およびその製造方法
AU2003273473A AU2003273473A1 (en) 2002-07-26 2003-07-25 Novel substituted pyrazolo(1,5 less thanigreater thanaless than/igreater than)-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same
CA2493402A CA2493402C (fr) 2002-07-26 2003-07-25 Nouvelles pyrazolo[1,5-a]-1,3,5-triazines substituees et leurs analogues, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation
US12/315,201 US20090105261A1 (en) 2002-07-26 2008-12-01 Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/09519 2002-07-26
FR0209519A FR2842809A1 (fr) 2002-07-26 2002-07-26 NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/315,201 Continuation US20090105261A1 (en) 2002-07-26 2008-12-01 Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same

Publications (2)

Publication Number Publication Date
WO2004011464A2 WO2004011464A2 (fr) 2004-02-05
WO2004011464A3 true WO2004011464A3 (fr) 2004-08-26

Family

ID=30011521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002354 WO2004011464A2 (fr) 2002-07-26 2003-07-25 Nouvelles pyrazolo[1,5-a]-1,3,5-triazines substituees et leurs analogiques, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation

Country Status (7)

Country Link
US (2) US20060106019A1 (fr)
EP (1) EP1525205A2 (fr)
JP (1) JP4794856B2 (fr)
AU (1) AU2003273473A1 (fr)
CA (1) CA2493402C (fr)
FR (1) FR2842809A1 (fr)
WO (1) WO2004011464A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850653A1 (fr) * 2003-02-04 2004-08-06 Univ Pasteur Derives de pyrazolotriazine, procede de preparation et utilisations
FR2851247B1 (fr) 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
TW200536536A (en) * 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
CA2720944C (fr) * 2008-04-07 2012-12-18 Irm Llc Composes et compositions en tant qu'inhibiteurs de kinase
MX2011007842A (es) * 2009-01-24 2012-01-12 Phytopharm Plc Tratamiento de trastornos mediados por factores neurotroficos.
FR2943058B1 (fr) 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
WO2011079231A1 (fr) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Composés qui modulent l'activité egfr et des procédés pour traiter ou prévenir des affections avec ceux-ci
WO2013179289A1 (fr) 2012-05-31 2013-12-05 Bio-Lab Ltd. Analogues de pyrazolotriazolyl-nucléosides et oligonucléotides les comprenant
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
CN109071467B (zh) * 2016-03-09 2023-04-04 艾丽奥斯生物制药有限公司 无环抗病毒药
KR102670626B1 (ko) * 2017-05-22 2024-05-29 토파두르 파마 아게 가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도
US20210032253A1 (en) * 2018-02-06 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
CN112479956A (zh) * 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
CN113801119B (zh) * 2021-08-30 2022-09-30 新乡医学院 一种吡唑并[1,3,5]三嗪类化合物的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2230366A1 (en) * 1973-05-22 1974-12-20 Sandoz Sa Pyrazolo(1,5-a)-s-triazines - and their salts, with bronchospasmolytic activity
WO1999038868A1 (fr) * 1998-01-28 1999-08-05 Du Pont Pharmaceuticals Company Azolo triazines et pyrimidines
WO2001023388A2 (fr) * 1999-09-30 2001-04-05 Neurogen Corporation Pyrazolo[1,5,-a]-1,5-pyrimidines et pyrazolo[1,5-a]-1,3,5-triazines amino substituees
WO2002050079A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
WO2002072202A1 (fr) * 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, ses enantiomeres et sels pharmaceutiquement acceptables en tant que ligands du recepteur de la corticoliberine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865824A (en) * 1972-03-07 1975-02-11 Icn Pharmaceuticals 2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines
US3846423A (en) * 1972-06-08 1974-11-05 Icn Pharmaceuticals Pyrazolo (1,5a) 1,3,5-triazines
US3910907A (en) * 1973-07-09 1975-10-07 Icn Pharmaceuticals Pyrazolo(1,5-a)-1,3,5-triazines
US3995039A (en) * 1975-05-27 1976-11-30 Merck & Co., Inc. Pyrazolo [1,5-a] [1,3,5] triazines
IL53783A (en) * 1977-02-03 1982-08-31 American Cyanamid Co Imidazo(1,5-d)-as-triazine-4 (3h)-(thi)one derivatives,their preparation and pharmaceutical compositions containing them
CH635587A5 (fr) * 1978-01-09 1983-04-15 Aron Sa Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation.
AU2192683A (en) * 1982-12-30 1984-07-05 Biomeasure Incorporated Pyrazolo(1,5-alpha)-1,3,5-triazines
CA1267143A (fr) * 1985-06-06 1990-03-27 Sun H. Kim Derives de 7-phenylpyrazole[1,5-a]-1,3,5-triazine, agents anti-arthrite
US4734414A (en) * 1985-06-06 1988-03-29 Biomeasure, Inc. Anti-inflammatory and anti-arthritic pyrazolo-[1,5-a]-1,3,5-triazine derivatives, compositions, and method of use therefor
US4824834A (en) * 1986-10-31 1989-04-25 Otsuka Pharmaceutical Company, Limited Pyrazolotriazine compounds
DE3722072A1 (de) * 1987-07-01 1989-01-12 Schering Ag 6,7-dihydro-pyrazolo(1,5-a)(1,3,5) triazin-2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider und pflanzenwuchsregulierender wirkung
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US5356894A (en) * 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
GB9111130D0 (en) * 1991-05-23 1991-07-17 Ici Plc Azole derivatives
AU667575B2 (en) * 1992-10-20 1996-03-28 Otsuka Pharmaceutical Co., Ltd. Condensed pyrazole derivatives, method of manufacturing the same, and androgen inhibitor
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
DE69428977T2 (de) * 1993-07-27 2002-07-11 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen Parkinsonsche Krankheit
US5358947A (en) * 1993-09-13 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones
JP3713783B2 (ja) * 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6166016A (en) * 1996-06-06 2000-12-26 Otsuka Pharmaceutical Factory, Inc. Amide derivatives
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
PT915880E (pt) * 1996-07-24 2007-12-31 Bristol Myers Squibb Pharma Co Azol triazinas e pirimidinas
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
DE19709877A1 (de) * 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CA2313004A1 (fr) * 1997-12-12 1999-06-24 David Cavalla Adenines 3-substitues via 2-thioxanthines
US6509338B1 (en) * 1998-06-22 2003-01-21 Bristol-Myers Squibb Company Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
DE19838705A1 (de) * 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one
CA2347950C (fr) * 1998-10-23 2005-05-03 Pfizer Inc. Inhibiteurs de cgmp pde5 de pyrazolopyrimidinone servant a traiter le dysfonctionnement sexuel
AU4331500A (en) * 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
CN1377354A (zh) * 1999-09-30 2002-10-30 纽罗杰有限公司 某些亚烷基二胺一取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
EP1244673A2 (fr) * 1999-12-24 2002-10-02 Bayer Aktiengesellschaft Nouveaux imidazo 1,3,5]triazinones et leur utilisation
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
US7067520B2 (en) * 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
AU2002229573A1 (en) * 2000-12-19 2002-07-01 Merck Patent Gmbh Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2230366A1 (en) * 1973-05-22 1974-12-20 Sandoz Sa Pyrazolo(1,5-a)-s-triazines - and their salts, with bronchospasmolytic activity
WO1999038868A1 (fr) * 1998-01-28 1999-08-05 Du Pont Pharmaceuticals Company Azolo triazines et pyrimidines
WO2001023388A2 (fr) * 1999-09-30 2001-04-05 Neurogen Corporation Pyrazolo[1,5,-a]-1,5-pyrimidines et pyrazolo[1,5-a]-1,3,5-triazines amino substituees
WO2002050079A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
WO2002072202A1 (fr) * 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, ses enantiomeres et sels pharmaceutiquement acceptables en tant que ligands du recepteur de la corticoliberine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RABOISSON, PIERRE ET AL: "A General Approach toward the Synthesis of C-Nucleoside Pyrazolo[1,5-a]-1,3,5-triazines and Their 3',5'-Bisphosphate C-Nucleotide Analogues as the First Reported in Vivo Stable P2Y1-Receptor Antagonists", JOURNAL OF ORGANIC CHEMISTRY (2002), 67(23), 8063-8071, XP002272644 *
ROBINS R K ET AL: "PURINE ANALOG INHIBITORS OF XANTHINE OXIDASE - STRUCTURE ACTIVITY RELATIONSHIPS AND PROPOSED BINDING OF THE MOLYBDENUM COFACTOR", JOURNAL OF HETEROCYCLIC CHEMISTRY, HETEROCORPORATION. PROVO, US, vol. 22, 1 May 1985 (1985-05-01), pages 601 - 634, XP002059789, ISSN: 0022-152X *

Also Published As

Publication number Publication date
JP2006502999A (ja) 2006-01-26
US20060106019A1 (en) 2006-05-18
AU2003273473A8 (en) 2004-02-16
EP1525205A2 (fr) 2005-04-27
CA2493402C (fr) 2012-05-01
AU2003273473A1 (en) 2004-02-16
CA2493402A1 (fr) 2004-02-05
FR2842809A1 (fr) 2004-01-30
JP4794856B2 (ja) 2011-10-19
WO2004011464A2 (fr) 2004-02-05
US20090105261A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
WO2003053330A3 (fr) Nouveaux composés
WO2004011464A3 (fr) Nouvelles pyrazolo[1,5-a]-1,3,5-triazines substituees et leurs analogiques, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation
WO2003092580A3 (fr) Methodes et compositions pour le traitement des troubles du systeme nerveux central et du systeme nerveux peripherique et nouveaux composes associes
WO2004055006A8 (fr) Nouveaux composes presentant un effet inhibiteur selectif de la gsk3
CA2316921A1 (fr) Composes azapolycycliques fusionnes avec un aryle
WO2004009549A3 (fr) Piperidines utiles pour traiter des maladies du systeme nerveux central
WO2003082853A8 (fr) Nouveaux composes
ZA200707901B (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
WO2004112719A8 (fr) Composes chimiques
CA2401229A1 (fr) Composes azapolycycliques a fusion aryle
WO2003095455A3 (fr) Composes therapeutiques
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200639156A (en) New compounds
WO2005040171A8 (fr) Derives de pyrazolo-pyrimidine et d&#39;imidazo-pyrimidine
SI1730144T1 (sl) Substituirane spojine 1,4,8-triazaspiro(4.5)dekan-2-on
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
WO2001000617A3 (fr) Nouveaux derives de piperazinyl-alkyl-thiopyrimidine compositions pharmaceutiques les contenant et procede de preparation de la substance active
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
HUP0103912A3 (en) Substituted alkylpyridazinone derivatives, process for their preparation, their use for the preparation of pharmaceutical compositions with anxiolytic activity
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2493402

Country of ref document: CA

Ref document number: 2004523885

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003755633

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003755633

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006106019

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10522497

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10522497

Country of ref document: US